Sorrento Therapeutics hires Mike Royal as Senior Vice President of Clinical
SAN DIEGO, March 3, 2014
SAN DIEGO, March 3, 2014 /PRNewswire/ --Sorrento Therapeutics, Inc. (NASDAQ:
SRNE; Sorrento) a late-stage clinical oncology company developing new
treatments for cancer and associated pain, today announced the addition of
anesthesiologist and pain specialist, Mike Royal, M.D., JD and MBA. He was
most recently Chief of Clinical Affairs at AcelRx.
"Mike's expertise in drug development and pain management is exceptional and
key to our success in advancing our clinical pipeline," said Henry Ji, Ph.D.,
President and Chief Executive Officer of Sorrento.
Dr. Royal commented, "I am very excited to join Sorrento during this period of
rapid growth and to lead the development ofSorrento's clinical pipeline of
oncologic and pain related assets. I look forward to working with the
Sorrento team to bring these groundbreaking targeted therapeutics to patients
Dr. Royalbrings more than 20 years of drug development experience where he
was a key contributor to over a dozen ANDAs, and several NDAs, most recently
Zalviso™ at AcelRx and Ofirmev^® at Cadence (currently being acquired by
Mallinckrodt). He is board certified in internal medicine, pain medicine,
anesthesiology with additional certification in pain management, addiction
medicine, and legal medicine. He has authored or co-authored more than 170
papers and abstracts. Previously, he was a clinical adjunct professor at the
University of California San Diego and the University of Oklahoma Medial
School, and a faculty member at the University of Pittsburg Medical Center.
He has also worked at Elan, Alpaharma and Solstice Neuroscience. He graduated
from the Massachusetts Institute of Technology in synthetic organic chemistry.
He earned his M.D. from the Massachusetts Medical School, law degree from the
University of Maryland School of Law, and MBA from TRIUM (NYU-Sern, HEC-Pairs
and the London School of Economics).
About Sorrento Therapeutics, Inc.
Sorrento is an oncology company developing new treatments for cancer and
associated pain. Sorrento's most advanced asset Cynviloq, the next-generation
paclitaxel, will commence its registrational trial and be developed under the
abbreviated 505(b)(2) regulatory pathway. Sorrento is also developing RTX, a
non-opiate TRPV1 agonist currently in a Phase 1/2 study at the National
Institutes of Health to treat terminal cancer patients suffering from
intractable pain. The Company has made significant advances in developing
human monoclonal antibodies, complemented by a comprehensive and fully
integrated ADC platform that includes proprietary conjugation chemistries,
linkers, and toxic payloads. Sorrento's strategy is to enable a multi-pronged
approach to combating cancer with small molecules, therapeutic antibodies, and
More information is available atwww.sorrentotherapeutics.com.
This press release contains forward-looking statements under the safe harbor
provisions of Section 21E of the Private Securities Litigation Reform Act of
1995 and subject to risks and uncertainties that could cause actual results to
differ materially from those projected. Forward-looking statements include
statements about the potential for the successful advancement of our
clinical-stage products; the retention of key personnel; and other matters
that are described in Sorrento's Annual Report on Form 10-K for the year ended
December 31, 2012, and subsequent Quarterly Reports on Form 10-Q filed with
the Securities and Exchange Commission, including the risk factors set forth
in those filings. Investors are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date of this
release and we undertake no obligation to update any forward-looking statement
in this press release except as required by law.
SOURCE Sorrento Therapeutics, Inc.
Contact: Mr. Amar Singh, EVP and Chief Business Officer, Sorrento
Therapeutics, Inc., firstname.lastname@example.org, T: + 1 (858) 210-3719,
Mr. Ian Stone, Account Director, Canale Communications, email@example.com, T:
+ 1 (619) 849-5388
Press spacebar to pause and continue. Press esc to stop.